NEJM Study Suggests Weekly Mosnodenvir Prevents Dengue in Human Model

New research published in The New England Journal of Medicine (NEJM) indicates that once-weekly mosnodenvir, a small-molecule antiviral, demonstrated protective effects in a human challenge model of dengue. This finding suggests mosnodenvir could serve as a potential new prophylactic treatment for dengue, a viral infection currently lacking an approved antiviral therapy. The development addresses a significant global health concern, particularly in regions where dengue is endemic.